Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease?

Affiliations

Editorial

Karla Cameron et al. Aliment Pharmacol Ther. 2022 Apr.

. 2022 Apr;55(8):1038-1039.

doi: 10.1111/apt.16843.

No abstract available

Comment on

Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Wong ECL, et al. Aliment Pharmacol Ther. 2022 May;55(9):1151-1159. doi: 10.1111/apt.16805. Epub 2022 Feb 15. Aliment Pharmacol Ther. 2022. PMID: 35166396 Clinical Trial.

1. Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17:411-418.e3.
1. Lewis JD, Rutgeerts P, Feagan BG, et al. Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn’s disease. Inflamm Bowel Dis. 2020;26:304-313.
1. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
1. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn’s disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568-576.
1. Wong ECL, Buffone E, Lee SJ, et al. End of induction patient-reported outcomes predict clinical remission but not endoscopic remission in Crohn’s disease. J Crohns Colitis. 2021;15:1114-1119.